



REFERENCES

- Aikwa, and Sugiyama, S. (2001):** An HMG-Co A reductase inhibitor, cerivastatin, suppress growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. **Circulation; 103: 276-283.**
- Ambrose, J.A.; Hjelm Dahl-Monsen, C.E.; Borrico, S. et al., (1988):** Angiographic demonstration of common link between unstable angina and Non Q-wave Myocardial infarction. **Am J Cardio; 61: 244-247.**
- Anderson, T.J.; Meredith, I.T.; Veung, A.C.; et al., (1995):** The effect of cholesterol lowering and antioxidant therapy on endothelial dependent coronary vasomotion. **N. Engl. J. Med; 322: 488-93.**
- Annika, R.; Lars, W.; Maarten, S.; et al. (2006):** Age, clinical presentation, and outcome of acute coronary syndromes in the Euro heart acute coronary syndrome survey. **Eur Heart J; 27: 789-795.**
- Antoine, Lafont, Cami, H. et al., (2003):** Plaque vulnerability mechanisms and detection predicts courses of revascularization.
- Apple, F.S.; Wu, A.H.; Mair, J. et al., (2005):** Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. **Clin chem.; 51: 810-824.**
- Arnault, C.; Burger, F.; Steffens, S.; et al., (2005):** Statins reduce interleukin 6-induced C-reactive protein in human hepatocytes: New evidence for direct anti-inflammatory effect of statins **Arterioscler thromb vasc Bio. 25: 1231-1236.**



- Badimon, J.J.; Lettinou, Toschiv, et al., (1999):** Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. **Circulation:99: 1780-1787.**
- Barter, P.; Nicholls, R. and Rye, K.A. (2004):** Anti- inflammatory properties of HDL. **Circ Res, 95: 769-772.**
- Bauriedle, G.; Heimer, J.; Beinert, T. et al (1994):** Colchicine antagonizes the activity of human smooth cells cultivated from arteriosclerotic lesion after atherectomy. **Coron Artery Dis S. 531. 531-539.**
- Ben-Chetrit, E. and Levy, M. (1998):** Colchicine; 1998 update. *Semin arthritis Rheum* 28. 48-59.
- Bobik, A.; Agrotis, A.; Kanellakis, P. et al., (1999):** Distinct pattern of transforming growth factor B isoform and receptor expressing in human atherosclerotic lesions. **Circulation. 99:2883-2891.**
- Bourcier, T. and Libby, P. (2000):** HMG CO- A reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. **Arterioscler Thromb vas Biol;:20:556-62.**
- Braunwald, E.(1989):** Unstable angina classification: **circulation: 80:410-414.**
- Brezinski, D.A.; Toiler, G.H.; Muller, J.E.; et al., (1988):** Morning increase in platelet aggregability: Association with a ssumption of the upright posture. **Circulation 78:35-40.**



- Budavari, Susan, Beinert, T. et al (1989):** Effect of Colchicine on hs - CRP and pharmacological basis of action . **Curr Drug targets inflamm Allergy 4.117-127.**
- Cannon, C.P.; Braunwald, E.; Mc Cabe, C.M. et al., (2004):** Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. **N Eng. J. Med., 350:1495-504.**
- Cerquaglia, C.; Diaco, M.; Nucera, G. et al (2005):** Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicines or analogues: an update. **Curr Drug targets inflamm Allergy 4.117-127.**
- Chaldakov, G.N. (1992):** Proposal for clinical trials using anti-inflammatory drugs in the therapy of angina pectoris, myocardial infarction and coronary re-stenosis after angioplasty and bypass grafting. **Med Hypotheses 37. 74-75.**
- Chen, Z.; Peto, R.; Collins, R. et al., (1991):** Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentration. **BM, (1991); 303:276-282.**
- Cholbanian, A.V. and Dzan, V.(1996):** Renin angiotensin system andtherosclerotic vascular disaease . in Fuster V, Ross R, Topol, EJ, Eds. Atherosclerosis and coronary artery disease vol-1. **Philadelphia; lippincoll-Rvaen, 237-42.**
- Clarkson, P.; Montgomery H.E.; Mullen, M.J. et al., (1999):** Exercise training enhances endothelial function in young men. **J Am coll Cardiol; 33:1379-1385.**



- Cohen, M.; Demers, C.; Gurfinkel, E.P.; et al., (1997):** A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery diseases. **N Engl J Med; 337:447-452.**
- Collins JF, Powloski, Dahmc et al., (1996):** The role of cytoskeleton in left ventricular pressure over load hypertrophy and failure. **J Mor Cell Cardiol 1996, 28;1435-1443.**
- Collis, Eligini, S.; Lalli, M.; et al., (1997):** Statins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. **Arterioscler thromb vas Biol:17:265-72.**
- Crisby, M.; shahpk, Yano, J.; et al., (1999):** Pravastatin treatment increases collagen content and decrease lipid content, inflammation, matrix metalloproteinases and cell death in human carotid plaques favouring lesion stability. **Circulation; 1(30 supp I): 1-469.**
- Danesh, J.; Colins, R. and Peto, R. (1997):** chronic infection and coronary heart disease: is there a link? **Lancet 350:430-436.**
- Danesh, Wheeler, J.G.; Hirschfield, et al., (2004):** C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. **N Engl J Med;350:1387–1397.**
- Dangas, G.; Badimon, J.J.H.; Smith, D.A. et al., (1999);** Pravastatin therapy in hyperlipidemia effects on thrombus formation and the systemic hemostatic profile. **J- Am Coll Cardiol; 33:1294-504.**
- David ,LaaksonenL , Niskanen, et al., (2010):** C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged



men: a population-based cohort study. *European Heart Journal* Volume 26, Issue 17 Pp. 1783-1789.

Davies, M.J. (1997): The composition of coronary-artery plaques. *N Engl J Med*; 336:1312-1314.

Davies, M.J.; Bland, J.M.; Hangartner, J.R.W.; et al., (1989): Factors influencing the presence or absence of a acute coronary artery thrombi in sudden ischemic death. *Eur Heart J.* 10:203-8.

Downs, J.R.; Clear field M.; Weis, S.G. et al., (1998): Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: result of AFCAPS/tex CAPS. Air force/ Tax as coronary Atherosclerosis prevention study. *JAMA.* 279:1615-1627.

Epstein, S.E. and Cannon, R.O. (1986): Site of increased resistance to coronary flow in patient with angina pectoris and normal epicardial coronary arteries. *J- Am coll cardiol*; 8:459-461.

Ernesto, R.; Ferreirós, M.D.; Carlos, P. et al., (1999): Independent Prognostic Value of Elevated C-Reactive Protein in Unstable Angina (*Circulation.*:1958-1963.).

Eto, M.; Kozai, Cosentino, F.; et al., (2002): Statins prevents tissue factor expression in human endothelial cells of Rho/Rho- Kinase and AKT pathway. *Circulation*; 105:1765-9.

Falke, (1985): Unstable angina with fatal outcome: Dynamic Coronary Thrombosis leading to infarction and /or sudden death. *Circulation*; 71: 699-709.



- Farb, A.; Burke, A.P.; Tang, A.L; et al., (1996):** Coronary erosion without rupture in to a lipid core: A frequent cause of coronary thrombosis in Sudden coronary death. **Circulation** **93**; 1354-1363.
- Flugelman, M.Y.; Virmani, R.; Correa, P. et al., (1993):** Smooth muscle cell abundance and fibroblast in coronary lesions of patients with non fatal unstable angina: A clue to the mechanism of transformation from the stable to unstable clinical state. **Circulation**; **88**:2493-2500.
- Ford, C.S. (1999):** Body mass index, diabetes and C-reaction protein among U.S adults. **Diabetes care**; **22**:1971-1977.
- François Schiele*, Nicolas Meneveau, et al** C-reactive protein improves risk prediction in patients with acute coronary syndromes Oxford Journals Medicine European Heart Journal Volume Pp. **290-297**.
- Fuster, V.(1999):** 50 I h anniversary historical article: Acute coronary syndromes: the degree and morphology of coronary stenosis. **J-Am coll cardiol.**; **34**:1854-1856.
- Gabay, C. and Kushner, I. (1999):** Acute phase proteins and other systemic responses to inflammation. **N Engle J Med**; **340**:448-454.
- Ganter, U.; Arcone, R.; Toniattic, et al., (1989):** Dual control of C-reactive protein gene expression by interleukine- I and Interleukine-6. **EMBO J**; **8**: 3773-3779.
- Goye, (1992):** Genesis of action of colchicine as strong anti-inflammatory drug.



- Gregory, G.; Schwartz, Anders G.; Olsson, Michael Szarek, et al., (2005):** Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome, an analysis of the Myocardial Ischemia Reduction with ACholesterol Loweriggressive ng (MIRACL) trial. **Diabetes Care** 28:2508-2513.
- Grignani, G.; Softlantino,F.; Zucchella, M.; et al., (1991):** Platelet activation by emotional stress in patients with coronary artery disease. **Circulation; 83 (Supl II): 128-136.**
- Grindling, K.K. and Alexander, R.W. (1997):** Oxidative stress and cardiovascular disease. **Circulation** 96:3264-5.
- Grundy, S.M.; Beker, D.; Clark, L. et al., (2001):** Expert panel on detection, evaluation, and treatment of High Blood cholesterol in Adults. Executive summary of the third report of the Natinal cholesterol education program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in Adults. (Adult treatment panel III). **JAMA; 285: 2486-97.**
- Grundy, SM.; Cleeman, J.I.; Mer, Z.C.N.; et al., (2004):** Implication of recent clinical trials for National cholesterol Education program Adult treatment panel III guidlines. **Circualtion; 110: 227-239.**
- Gupta, S.; Leathan, E.W.; Carrington, D.; et al., (1997):** Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and a zithromycin in male survivors of myocardial infraction. **Circulation, 96; 404-407.**
- Haim, M.; Battler, A.; Behar, S.; et al., (2004):** Acute coronary syndromes complicated by symptomatic and asymptomatic heart



failure: does current treatment comply with guidelines? **Am Heart J**; 148(2):325.

Hajjar, K.A. (1993): (Homocysteine- induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. **J I Clin Invest**, 91: 2873-9.

Hansson, G.K. (2002): Inflammatory markers correlate with coronary lesion morphology in patients with unstable angina. **European Heart Journal Vol; Abst. Suppl. August, pag 468.**

Hansson, G.K. (2005): Inflammation, atherosclerosis, and coronary artery disease. **N Engl J Med** 352. 1685-1695.

Howard, G.; Wagenket, L.; Burke, G.; et al., (1998): for the ARIC investigators: Cigarette smoking and progression of atherosclerosis; the Atherosclerosis Risk in Communes (AR1C) study. **JAMA**; 279: 119-124.

Ikonomidis, I.; Andreotti, E.; Economou, E. et al., (1999): Increased pro inflammatory cytokines in patient with chronic stable angina and their reduction by Aspirin. **Circulation**; 100: 793-798.

Insull, W.; Isaa sohn, J.; Kwiterovitch, P. et al., (2000): Efficacy and safety cerivastatin 80mg in patient with hypercholesterolemia: the pivotal placebo-controlled clinical trial. **J Int Med Res**; 28:47-68.

Jilial, I.; Stein, D.; Balis, D.; et al., (2001): Effect of hydroxyl methyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reaction protein level. **Circulation**; 103:1933-5.



- Juliek, Plenge, M.I.; Tcril et al., (2002):** Simvastatin lowers C-reactive protein within 14 days an effect independent of low density lipoprotein cholesterol reduction. **Circulation: 106: 1447-14520.**
- Kaluyoglue, M.V.; Hoerneman, B.; La Verda, D.; et al., (1999):** Celluar oxidation of low density lipoprotein by Chlamydia pneumoniae. **J Infect Dis, 180:780-790.**
- Kim KY, Ralph Schumacher H, Hunsche E et al., (2003):** Aliterature of review of epidemiology and treatment of gout. **Clin : 25;1593-617.**
- Kleinveld, H.A.; Demaker, P.N.; De Hann, A.F. et al., (1993):** Decreased in vitro oxidzability of low density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy- 3methyl glutaryl- Co A reductase. Inhibitors. **Eur J Clin. Invest, 23: 289-295.**
- Kruth, H.S. (1997):** The fate of lipoprotein cholesterol entering the arterial wall. **Curr. Opin. Lipidol, 8:246-252.**
- Kumar, S.V.; Ramizi, S. and Stantely, L. et al., (1993):** Pathology of atherosclerosis. In: Basic pathology, 5th ed. Milchell, J. (E, d) WB Saunders company, Philad. **London, Toronto, 278.**
- Lanza, G.A.; Fillippis, Sestitof, et al., (2002):** Prognostic value of pre-discharge exercise testing and serum C-reactive protein in patient with unstable angina. **Ital Heart; 3(11): 643-9.**
- Lau, F. and Liao, J.K. (1998):** Post transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. **J Biol Chem; 273:24266-71.**



- Lekakis, J.P.; Vamvakou, A.; Andreadou I. et al (2006):** Divergent effects of rofeoxib on endothelial function and inflammation in acute coronary syndromes. **Int J Cardiol 112. 359-366.**
- Leslie, E.; Goeffry, J. and Jamc, M. (1991):** Statistical analysis in interpretation and uses of medical statistic. Oxford scientific puplication, (Pub), PP.411-6.
- Libby, P. (2001):** Current concepts of pathogenesis of acute coronary syndromes. **Circulation.104: 365-372.**
- Liuzzo, G.; Biasucci, L.M.; Gallimore, J.R. et al., (1994):** the prognostic vlaue of C-reactive protein and serum amyloid A protein in sever unstable angina. **N Eng. J Med.; 331: 417-424.**
- Macy, E.M. Hayes, I.E. and Tracy, K.P. et al., (1997):** Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals are epidemiological applications. **Clin Chem, 43:52-58.**
- Mall at Z., Hugel, B.; Ohan, J. et al., (1999):** Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques a role for apoptosis in plaque plaques a role for apoptosis in plaqlue thrombogenicity: **Circulation. N; 26:99 (3): 348-53.**
- Mark, Nidorf, Thompson Peter, et al., (2007):** Effect of Colchicine (0.5 mg twice daily) on high-sensitivity c-reactive protein independent of Aspirin and Atorvastatin in patients with stable coronary artery disease. **The American journal of cardiology pp 805-807.**



- Mc. Fadden, E.P.; Clarke, J.C.; Davies, C.J. et al., (1991):** Effect of intracoroanry serotonin on coronary vessels in patient with stable angina and patient with varient angina. **N Eng. J. Med** 324: 648-654.
- Merlini, P.A.; Bauer, K.A.; Olteronal, et al., (1994):** Presistance activation of coagulation mechanism in unstable angina and myocardial infarction. **Circulation** 90: 61-68.
- Mora, S. and Ridker, P.M. (2006):** Justification for the use of statins in primary prevention: an intervention trial evaluation Rosuvastatin (JUPITER). Can C-reactive protein by used to target statin therapy in primary prevention? **Am J Cardiol** 97. (suppl): 33A-41 A.
- Moreno, P.R.; Bernard, V.H.; Lopez-Cuellar, J. et al., (1996):** Macrophage, smooth muscle cells and tissue factor in unstable angina: implication for cell mediated thrombogensity in acute coronary syndromes. **Circulation** 94: 3090-3097.
- Morrow, D.A. and BraunWald, E. (2003):** Future of biomarkers in acute coronary syndromes. **Circulation**. 108: 250.
- Navab, M.; Berliner, J.A.; Watson, A.D. et al., (1996):** the yinand yang of oxidation in the development of the fatty streak. A review based on the 1994 George lyman Duff Memorial lecture. **Arterioscler thromb vase Biol**, 16:831-92.
- Nehler, M.R.; Taylor, L.M.; Porter, et al., (1997):** Homocysteinemia as a risk factor for atherosclerosis. A review. **Cardio vasc. Surg**. 6:559-67.



- Nesto, R.W.; Waxman, S.; Mittelman, M.A., et al., (1998):** Angioscopy of culprit coronary lesions in unstable angina pectoris and correlation of clinical presentation with plaque morphology. **AM J. Cardiol** 81, 1:225-228.
- Nicolosi, R.J.; Wilson, T.A. Krauss, B.R. (1998):** The ACAT inhibitor cholesterol is effective in the prevention and regression of aortic fatty streak area in hamsters. **Atherosclerosis**; 137: 77-85.
- Ortego, M.; Busto S.C.; Hernandez-Presa, M.A. et al., (1999):** Atorvastatin reduce NFkB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. **Atherosclerosis**; 147: 253-61.
- Palmeri, S.T.; Lowe, A.M.; Hochman, J.S. et al., (2005):** Racial and ethnic differences in the treatment and outcome of cardiogenic shock following acute myocardial infarction. **Am J Cardiol**; 96:1042-1049
- Patel, T.M.; Shishehbor, M.N.; Bhatt, et al., (2007):** A review of high dose statin therapy targeting cholesterol and inflammation in atherosclerosis. **European heart Journal**, 28:664-672.
- Paul, M.; Ridker, M.D.; MPH, Nader, Rifai, P.H.D. et al., (2001):** Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. **N Eng. J Med.** 344:1592.-65.
- Pepys, M. (1981):** C-reactive protein fifty years on **Lancet**; 653-65.
- Poloński, L.; Mariusz, G.; Marek, G.; et al., (2007):** Characteristics, treatments and outcomes of patients with acute coronary



syndromes in Poland: Polish Registry of Acute Coronary Syndromes (PL-ACS). *Kardiologia Polska*; 65: 8.

Ridker, P.M.; Cammon, C.P.; Morrow, D.; et al., (2005): C-reactive protein levels and outcomes after statin therapy. **N Eng. J. Med.** 352:20-25.

Ridker, P.M.; Rifai, N.; Rose, L.; Buring, et al., (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *New England Journal of Medicine.*;347(20):1557–1565.

Rocha, S.; Nabais, S.; Marques, J.; Correia, A. et al., (2007): Heart failure after acute coronary syndrome: identify to treat better. *Rev Port Cardiol.*; 26(4):349-59.

Rogers, W.J.; Canto, J.G.; Lambrew, C.T.; et al., (2000): Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2, and 3. *J Am Coll Cardiol*; coronary reocclusion and recurrent ischemia after thrombolysis: a metaanalysis. *J Am Coll Cardiol*; 19:671-677.36: 2056–2063.

Rosenberg, R.D. and Aird, W.C. (1999): Vascular-bed- spesfic hemostasis and hypercoagulable states. **N Eng J Med**, 340: 1555-1569.

Ross, R. (1999): Atherosclerosis, an inflammatory disease. **New Eng J Med**, 340:115-126.



- Sabatime, M.S.; Morrow, D.A.; Jablons, Kike, A. et al., (2007):** Prognostic significance of the centers for disease control American Heart Association high- sensitivity C-reactive protein cut points for cardio vascular and other outcomes in patient with acute coronary syndrome. **Circualtion, 115: 1528-1536.**
- Santos, E.S.; Minuzzo, L.; Pereira, M.P.; et al., (2006):** Acute coronary syndrome registry at a cardiology emergency center. **Arq Bras Cardiol; 87(5):597-602.**
- Selwyn, A.P.; Kinlay, S.; Libby, P.; et al., (1997):** Atherogenic lipid, vascular dysfunction, and clinical signs of ischemic heart disease. **Circulation; 95: 5-7.**
- Shah, P. and Fuster, V. (1995):** Coronary plaque distribution. **Circulation; 92:657-671.**
- Shepherd, J.; Cobbe, S.M.; Ford, I. et al., (1995):** For the West Of Scotland Coronary prevention Study group. Prevention of conronary heart disease. With pravastatin in men with hypercholesteremia. **N. Eng. J Med; 333: 1301-1307.**
- Shishehbor, H.M. and Hazen, S.L. (2004):** Inflammatory and oxidative markers in atherosclerosis: relation ship to outcome. **Curr Atheroscelr Rew; 6: 243-250.**
- Silber, S.; Albertson, P.; Aviles, F.F.; et al., (2005):** Guidelines for percutaneous coronary interventions, the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. **Eur Heart J; 26: 804-847.**



- Stampfer, M.J.; Henekens, C.H.; Manson, J.E.; et al., (1993):** Consumption and the risk of coronary disease in women. **N. Eng. J Med; 328:1444-1449.**
- Steg, P.G.; Arthur, K.; Frans, V.; et al., (2008):** Impact of in-hospital revascularization on survival in patients with NSTEMI-ACS and congestive heart failure. **Circulation; 118:1163-1171.**
- Steinberg, D. (1997):** Low density lipoprotein oxidation and its pathobiological significance. **J Biol Chem, 272: 20963-6.**
- Stephens, N.G.; Parosns, A.; Schofield, P.M.; et al., (1996):** Randomized controlled trial of vitamin E in patient with coronary heart disease: Cambridge Heart Antioxidant Study. **Lancet; 347: 781-786.**
- Sugiishi, M. and Takatsu, F. (1993):** Cigarette smoking is a major risk factor for coronary spasm. **Circulation, 87: 76-79.**
- Tamin, S.; Carluceio, E.; Bentivoglio, M. et al., (1999):** C-reactive protein as a marker of Cardiac ischemic events in the year after a first un complicated myocardial infarction. **Am J Cardio; 83: 1595-1599.**
- Tracy, R.; Lemaitre, R.; Psaty, B. et al., (1997):** Relation ship of C-reactive protein to risk of cardio vascular disease in the elderly: results from cardiovascular health study and the Rural health promotion project. **Arterioscler thromb vas Biol; 17:1121-1127.**
- Vander, Wal, A.C.; Becker, A.E.; Vander Loss, C.M. et al., (1999):** Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaque is characterized by on inflammatory



process irrespective of the dominant plaque morphology. **Circulation; 89:36-44.**

Vasa, M.; Fichtether, S.; Archer, A. et al., (2001): Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. **Circ Re; 6:89 (1): E1-7.**

Virmani, R.; Kolodgic, F.D.; Burke, A.P. et al., (2000): Lessons from sudden coronary death. A comprehensive morphological classification scheme for atherosclerotic lesions. **Arterioscler thromb vas Biol; 20 (5): 3262-75.**

Wannamethee, S.G.; Sliaper, A.C.; Wliincup, P.H. et al., (1995): Smoking cessation and the risk of stroke in middle aged men. **JAMA, 274:155-160.**

Weiss, E.J.; Bray, P.F.; Tayback, M. et al., (1996): A polymorphism of the platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. **N Eng J MED: 339: I 090-1097.**

Wessiman, Riedker M.; Market, C. et al., (2009): Mechanism of action of colchicine, genetic basis.

Yilmaz Ozbay,* Mehmet Akbulut, Mehmet Balin, et al., (2007): The Level of hs-CRP in Coronary Artery Ectasia and Its Response to Statin and Angiotensin-Converting Enzyme Inhibitor Treatment.

Yusuf, S.; Sleight, P.; Pogue, Z. et al., (2000): Effect of Angiotensin converting enzyme. Ramipril on cardiovascular event in high risk patients. **N Eng. J Med, Mar 9:342.**



Zebrack, J.S.; Muhlestein, J.B. et al, (2002): C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. **J. Am. Coll. Cardiol.**;39:632–637.

Zeihner, A.M.; Schachinger, V. and Minners, J. et al., (1995): Long term cigarette smoking impairs endothelium dependant coronary arterial vasodilator function. **Circulation**; 92:1094-110.

Zwaka, T.P.; Hombach, V.; Torzewski, J. et al., (2001): C-reactive protein- mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. **Circulation**; 103:1194-7.